Recruiting

Testing a new drug to prevent eye melanoma from returning

Plain-English translation of NCT06246149 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a drug called to see if it can help prevent eye melanoma from coming back after you've had surgery or radiation. About half of patients with high-risk eye melanoma experience a recurrence, so researchers want to know if this medication — which has already shown promise in patients with advanced melanoma — might help stop that from happening in the first place.

Currently, doctors can only watch and wait after treating high-risk eye melanoma, with no proven treatment to prevent the cancer from returning. This medication has already been shown to help patients whose melanoma has spread, so researchers believe it might work earlier to stop recurrence before it starts.

Do you qualify?

You likely qualify if…

you have been diagnosed with high-risk eye melanoma (not including iris melanoma) and have recently completed surgery or radiation treatment
you are within 11–12 weeks of finishing your primary treatment
you have a specific genetic marker (HLA-A*02:01 positive)
you are 18 years or older with good overall health status (ECOG 0 or 1)
you have no evidence of cancer recurrence on recent imaging scans
you are able to use effective birth control during and for 6 months after treatment (if of childbearing age)

You likely don't qualify if…

you have significant or uncontrolled heart disease, heart failure, uncontrolled high blood pressure, or abnormal heart rhythm requiring treatment
you have had a heart attack or unstable chest pain within the last 6 months
you currently have an active infection requiring antibiotics or active viral infections (hepatitis B or C, or HIV)
you have severe kidney disease or have received a kidney transplant
you are pregnant, breastfeeding, or unwilling to use birth control during the study

What participation looks like

If you join this trial, you'll either receive the new medication or be in the observation group. Those receiving the medication will get weekly infusions for 6 months (starting with smaller doses in weeks 1 and 2, then a full dose from week 3 onward, for a maximum of 26 infusions). You'll need regular check-ups and scans to monitor your health and watch for any signs of cancer returning. The whole trial lasts about 6 months for the active treatment phase, with follow-up monitoring after that.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(15 sites)

United States

Northwell Health -Center for Advanced Medicine, Lake Success, New York

Belgium

Cliniques Universitaires Saint-Luc, Brussels

France

Centre Antoine Lacassagne, Nice

Institut Curie - Hôpital de Paris, Paris

Germany

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin